Dr. Reddy's Laboratories reported mixed results for the first quarter of fiscal 2025, with earnings per share falling slightly to $1, missing analyst estimates of $1.10, while revenues surged 14% year-over-year to $921 million, surpassing expectations. The revenue growth was driven by strong performances in global generics, particularly in North America and India, although this was partially offset by price erosion in certain markets. Despite the revenue increase, net profit declined marginally (0.8%-1%) to around Rs 1,392 crore, impacted by higher expenditures and unfavorable foreign exchange rates. The company's gross margin improved to 60.4% due to a favorable product mix. Dr. Reddy's continues to focus on its generics business while making strategic investments in biologics, consumer healthcare, and innovation. The board also approved a 1:5 share split.